AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04738461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The Posterior Glenohumeral Capsule Stretching Exercise, Pectoral Stretching Exercise, Push-up Against Wall Exercise, Scapular Plan Exercise, 90 Degree Shoulder Flexion Exercise, Isometric External Rotation Exercise and Isometric Internal Rotation Exercise will be applied according to the severity of the disease and the size of the disability.
Study NCT04738461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: Active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
Study NCT04738461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Group
Description: The same exercise program applied to telerehabilitation group.
Study NCT04727372 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A structured questionnaire will be served to each participant of study after getting the verbal consent from him for inclusion into the study
Study NCT06003348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OHCit- standard dose
Description: Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
Study NCT06003348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Citrate
Description: 10 mEq Extended-release tablets for oral use
Study NCT06003348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06003348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OHCit- low dose
Description: Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
Study NCT06193226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy can be done in two ways:~1. Open technique: Using cotton swabs or a cryogun spray, the cryogen is delivered directly to the lesion in this technique.~2. Closed technique: Cryo-probes are used to apply the cryogen to the lesion in this procedure.~The spray's nozzle of the Cryogun spray -50 ◦C was situated 1 cm away from the skin's surface and applied on the oral lesion for 30 seconds. Each freezing cycle lasted 10 to 30 seconds, with the subsequent 60-second thaw interval lasting twice as long as the freezing time. The ice ball that formed during freezing was totally melted before the subsequent freezing process could begin.~The application process should went from the core out to the edges. The management of lesions that are too big to be frozen by a single spray requires many overlapping treatments of liquid nitrogen. Mucoceles and erosive lichen planus took 30 to 50 seconds to freeze, whereas fibromas and leukoplakia took 60 to 70 seconds.
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
Study NCT05839158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFMT cell suspension
Description: Perform FUE autologous hair transplantation on the patient according to the guidelines and standard procedures. During the procedure, a hollow punch is used to individually punch out follicular units from the donor area. The epidermis, some dermis tissue, sebaceous glands, and surrounding tissue of the follicular units are separated and removed before the remaining follicular tissue is implanted into the recipient area. The separated tissue is trimmed with surgical scissors to create a cell suspension. After completion of the procedure, the HFMT cell suspension is evenly applied to the treatment group surface. Double vaseline gauze is used to cover all donor areas and is then wrapped with sterile dry gauze with moderate pressure.
Study NCT05839158 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mupirocin ointment
Description: the Minoxidil ointment is evenly applied to the control group surface.
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
Study NCT03593252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nil per os
Description: Fasting orders according to anesthesia prior to surgery: No solid for >=8 hours, no formula milk/full liquids >= 4hours; no breast milk or clear fluids >=2hours.
Study NCT03593252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nil per os
Description: Fasting orders according to anesthesia prior to surgery: No solid for >=8 hours, no formula milk/full liquids >= 4hours; no breast milk or clear fluids >=2hours.
Study NCT03593252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nil per os
Description: Fasting orders according to anesthesia prior to surgery: No solid for >=8 hours, no formula milk/full liquids >= 4hours; no breast milk or clear fluids >=2hours.
Study NCT06167811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body electrical stimulation
Description: Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
Study NCT03593252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clear fluids the day before surgery
Description: As part of bowel preparation, participants will be asked to stick to clear fluids following breakfast the day before surgery. Breast milk is allowed if applicable.
Study NCT05353504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: 28g/day delivered in 2 sachets throughout the day with main meals
Study NCT05353504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: weekly educational sessions to improve individual's eating behaviour
Study NCT05353504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equicaloric maltodextrin delivered in 2 sachets throughout the day with main meals
Study NCT04708249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiroinositol
Description: Supplementation with 600 mg of D-chiroinositol, two-times daily on an empty stomach, for 30 days.
Study NCT06412614 — intervention group
Intervention type: OTHER
Intervention: disease phenotype
Description: evaluation of SSc phenotypes
Study NCT06214091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal decompression
Description: Gastric tube is inserted within 24-hour severe ischemic stroke attack; gastrointestinal decompression is performed for 48 hours.
Study NCT06214091 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Gastric tube is inserted within 24-hour severe ischemic stroke attack.
Study NCT05349006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Dose related to weigh (100 mg for \<50 kg, 150 mg 50-100 kg, 200 mg for >100 kg) = 2 to 4 50mg oral caps, daily, during all the study period
Study NCT05349006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose related to weigh (100 mg for \<50 kg, 150 mg 50-100 kg, 200 mg for >100 kg) = 2 to 4 50mg oral caps, daily, during all the study period
Study NCT05733312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system
Description: Focused ultrasound which targets energy to a specific area in the brain based on imaging and disrupts the blood brain barrier which keeps certain drugs and other molecules out of the brain.
Study NCT05688722 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supine position
Description: Patients preoxygenated in supine position before endotracheal intubation
Study NCT05688722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 20 degree head elevation position
Description: Patients preoxygenated in 20 degree head elevation position before endotracheal intubation
Study NCT05688722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 30 degree head elevation position
Description: Patients preoxygenated in 30 degree head elevation position before endotracheal intubation
Study NCT05688722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 45 degree head elevation position
Description: Patients preoxygenated in 45 degree head elevation position before endotracheal intubation
Study NCT02327455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Dobutamine Echocardiographic using 4DE System
Description: Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
Study NCT06522321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF and FDBA
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with FDBA and I-PRF (experimental group) will be placed according to the standard protocol.~An immediate implant with FDBA( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with sutures
Study NCT04893304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: co2 laser
Description: types of laser
Study NCT05620693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 TCR-T
Description: NY-ESO-1 TCR-T treatment
Study NCT06354816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 10% pump spray
Description: First volunteers will undergo insertion of PIVC into the vessel of dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Lidocaine spray 10 % serves as a local anesthesia is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge.
Study NCT06354816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline solution isotonic 0.9% NaCl
Description: First volunteers will undergo insertion of PIVC into the vessel at dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Physiological saline solution serves as a placebo and is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge.
Study NCT06520293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Beverage
Description: A beverage containing different sweet ingredients.
Study NCT06520293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sweet Beverage
Description: A beverage containing different sweet ingredients.
Study NCT05801835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (cytarabine: daunorubicin) liposome for injection
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
Study NCT05801835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
Study NCT05801835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (cytarabine: daunorubicin) liposome for injection
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
Study NCT05801835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
Study NCT04146428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinician-mediated JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
Study NCT04146428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-mediated JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
Study NCT05025436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupoint stimulation with low energy laser (Erger laser pen)
Description: Each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, The power is 200mW, and the Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module is selected according to the acupoints. The treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, after a 2-week pause, After the two groups crossed for 4 weeks, each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) with low-energy laser (Erjie laser pen) acupoint stimulation. Set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and treatment dose is 3 joules per acupoint three times a week for a period of time 4 weeks.
Study NCT05856136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection
Description: Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
Study NCT06103253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: a Bla80 group
Description: the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.
Study NCT06103253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: a Bla80 group
Description: the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.
Study NCT06050044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A (hyperbaric bupivacaine)
Description: Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution
Study NCT06050044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)
Description: Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
Study NCT05311813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin, Hydroxychloroquine
Description: To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
Study NCT05311813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin, Hydroxychloroquine
Description: To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
Study NCT04686032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced early Rehabilitation Program
Description: Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS\* for incisional pain (30min)
Study NCT04708236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTD-1 low dose
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Study NCT04708236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTD-1 mid dose
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Study NCT04708236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTD-1 high dose
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.
Study NCT04708236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Vehicle Control will be administered intravenously once daily for 5 consecutive days.
Study NCT05750446 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Riociguat (BAY 63-2521)
Description: A selective stimulator of soluble guanylate cyclase (sGC)
Study NCT05750446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT04684238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Solution for Injection/Infusion
Study NCT04684238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
Study NCT05071768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused ACT
Description: Brief acceptance and commitment therapy
Study NCT04686032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early ambulation
Description: Patient education \& Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
Study NCT04793256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride).
Description: 5% sodium fluoride Varnish is a fluoride varnish which is applied to tooth surfaces
Study NCT04793256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin based fissure sealant (3M Clinpro Sealant)
Description: teeth will be isolated with cotton rolls and saliva ejector than etching for pits and fissure sealant
Study NCT05022797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase 1000 UNT [Voraxaze]
Description: 2 vials of 1000 units per vial
Study NCT06493474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: PEER ASSISTED BREASTFEEDING EDUCATION PROGRAM
Study NCT06493474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Non education program only routine care
Study NCT05149105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation
Description: On D0, in the operating room, argon plasma coagulation will be performed around the perimeter of the anastomosis for a period of 5 to 10 min under general anesthesia. The removal of the catheter and the endoscope will be carried out under control. Patients will be kept under surveillance the night following the procedure. A liquid diet will be prescribed for 10 days. The follow-up will be carried out on an outpatient basis with a control endoscopy at 2 months, followed by a new procedure in the event of an anastomosis larger than 1.5 cm. A new endoscopic check will be carried out at 4 months if an argon plasma coagulation was performed during the previous check, with a third and last argon plasma coagulation if an anastomosis of more than 1.5 cm persists. The number of procedures will therefore be a maximum of 3. A control endoscopy will be performed at one year for the final control of the anastomosis.
Study NCT06320587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care practice by both mother and father
Description: In this group, kangaroo care will be done by both mother and father. Mothers used the Mother-Infant Attachment Scale and the Perceived Maternal Parenting Self-Efficacy Scale as pretests; Fathers will also complete the Postpartum Father-Infant Attachment Survey and the Perceived Father Parenting Self-Efficacy Form. Mothers and fathers in the application group will be provided with kangaroo care for 45 minutes, 2 days a week for 5 weeks. The baby's vital signs will be monitored 30 minutes before each kangaroo care, at the 15th minute of each kangaroo care, and 30 minutes after the kangaroo care, and will be recorded on the Kangaroo Care Monitoring Form. After kangaroo care was completed at the end of 5 weeks, mothers used the Mother-Baby Attachment Scale and the Perceived Mother Parenting Self-Efficacy Scale as posttests; Postnatal Father-Infant Attachment Questionnaire and Perceived Father Parenting Self-Efficacy Form will be filled out by fathers.
Study NCT06320587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kangaroo care practice only mother
Description: In the control group, only the mother will care for the kangaroo. The application will be similar to the experimental group.
Study NCT06062186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 650 mg of placebo, given as two capsules containing maltodextrin
Study NCT06062186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AmaTea Guayusa Extract
Description: 650 mg of AmaTea Guayusa Extract, given as two capsules
Study NCT06062186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lion's Mane
Description: 1000 mg of Lion's Mane, given as two capsules